BACKGROUND: Higher lipoprotein-associated phospholipase A(2)(Lp-PLA2) activity is associated with increased risk of coronary heart disease (CHD), making Lp-PLA2 a potential therapeutic target. PLA2G7 variants associated with Lp-PLA2 activity could evaluate whether this relationship is causal. METHODS AND RESULTS: A meta-analysis including a total of 12 studies (5 prospective, 4 case-control, 1 case-only, and 2 cross-sectional studies; n=26 118) was undertaken to examine the association of the following: (1) Lp-PLA2 activity versus cardiovascular biomarkers and risk factors and CHD events (2 prospective studies; n=4884); (2) PLA2G7 single-nucleotide polymorphisms and Lp-PLA2 activity (3 prospective, 2 case-control, 2 cross-sectional studies; up to n=6094); and (3) PLA2G7 single-nucleotide polymorphisms and angiographic coronary artery disease (2 case-control, 1 case-only study; n=4971 cases) and CHD events (5 prospective, 2 case-control studies; n=5523). Lp-PLA2 activity correlated with several CHD risk markers. Hazard ratios for CHD events for the top versus bottom quartile of Lp-PLA2 activity were 1.61 (95% confidence interval, 1.31 to 1.99) and 1.17 (95% confidence interval, 0.91 to 1.51) after adjustment for baseline traits. Of 7 single-nucleotide polymorphisms, rs1051931 (A379V) showed the strongest association with Lp-PLA2 activity, with VV subjects having 7.2% higher activity than AAs. Genotype was not associated with risk markers, angiographic coronary disease (odds ratio, 1.03; 95% confidence interval, 0.80 to 1.32), or CHD events (odds ratio, 0.98; 95% confidence interval, 0.82 to 1.17). CONCLUSIONS: Unlike Lp-PLA2 activity, PLA2G7 variants associated with modest effects on Lp-PLA2 activity were not associated with cardiovascular risk markers, coronary atheroma, or CHD. Larger association studies, identification of single-nucleotide polymorphisms with larger effects, or randomized trials of specific Lp-PLA2 inhibitors are needed to confirm or refute a contributory role for Lp-PLA2 in CHD.
BACKGROUND: Higher lipoprotein-associated phospholipase A(2)(Lp-PLA2) activity is associated with increased risk of coronary heart disease (CHD), making Lp-PLA2 a potential therapeutic target. PLA2G7 variants associated with Lp-PLA2 activity could evaluate whether this relationship is causal. METHODS AND RESULTS: A meta-analysis including a total of 12 studies (5 prospective, 4 case-control, 1 case-only, and 2 cross-sectional studies; n=26 118) was undertaken to examine the association of the following: (1) Lp-PLA2 activity versus cardiovascular biomarkers and risk factors and CHD events (2 prospective studies; n=4884); (2) PLA2G7 single-nucleotide polymorphisms and Lp-PLA2 activity (3 prospective, 2 case-control, 2 cross-sectional studies; up to n=6094); and (3) PLA2G7 single-nucleotide polymorphisms and angiographic coronary artery disease (2 case-control, 1 case-only study; n=4971 cases) and CHD events (5 prospective, 2 case-control studies; n=5523). Lp-PLA2 activity correlated with several CHD risk markers. Hazard ratios for CHD events for the top versus bottom quartile of Lp-PLA2 activity were 1.61 (95% confidence interval, 1.31 to 1.99) and 1.17 (95% confidence interval, 0.91 to 1.51) after adjustment for baseline traits. Of 7 single-nucleotide polymorphisms, rs1051931 (A379V) showed the strongest association with Lp-PLA2 activity, with VV subjects having 7.2% higher activity than AAs. Genotype was not associated with risk markers, angiographic coronary disease (odds ratio, 1.03; 95% confidence interval, 0.80 to 1.32), or CHD events (odds ratio, 0.98; 95% confidence interval, 0.82 to 1.17). CONCLUSIONS: Unlike Lp-PLA2 activity, PLA2G7 variants associated with modest effects on Lp-PLA2 activity were not associated with cardiovascular risk markers, coronary atheroma, or CHD. Larger association studies, identification of single-nucleotide polymorphisms with larger effects, or randomized trials of specific Lp-PLA2 inhibitors are needed to confirm or refute a contributory role for Lp-PLA2 in CHD.
Authors: Robert L Wilensky; Yi Shi; Emile R Mohler; Damir Hamamdzic; Mark E Burgert; Jun Li; Anthony Postle; Robert S Fenning; James G Bollinger; Bryan E Hoffman; Daniel J Pelchovitz; Jisheng Yang; Rosanna C Mirabile; Christine L Webb; LeFeng Zhang; Ping Zhang; Michael H Gelb; Max C Walker; Andrew Zalewski; Colin H Macphee Journal: Nat Med Date: 2008-09-21 Impact factor: 53.440
Authors: Sarah H Wild; Christopher D Byrne; Felicity B Smith; Amanda J Lee; F Gerald R Fowkes Journal: Diabetes Care Date: 2006-03 Impact factor: 19.112
Authors: Yangsoo Jang; Oh Yoen Kim; Soo Jeong Koh; Jey Sook Chae; Young Guk Ko; Ji Young Kim; Hongkeun Cho; Tae-Sook Jeong; Woo Song Lee; Jose M Ordovas; Jong Ho Lee Journal: J Clin Endocrinol Metab Date: 2006-06-20 Impact factor: 5.958
Authors: D M Stafforini; K Satoh; D L Atkinson; L W Tjoelker; C Eberhardt; H Yoshida; T Imaizumi; S Takamatsu; G A Zimmerman; T M McIntyre; P W Gray; S M Prescott Journal: J Clin Invest Date: 1996-06-15 Impact factor: 14.808
Authors: I Juhan-Vague; P E Morange; C Frere; M F Aillaud; M C Alessi; E Hawe; S Boquist; P Tornvall; J S Yudkin; E Tremoli; M Margaglione; G Di Minno; A Hamsten; S E Humphries Journal: J Thromb Haemost Date: 2003-11 Impact factor: 5.824
Authors: Harald Grallert; Josée Dupuis; Joshua C Bis; Abbas Dehghan; Maja Barbalic; Jens Baumert; Chen Lu; Nicholas L Smith; André G Uitterlinden; Robert Roberts; Natalie Khuseyinova; Renate B Schnabel; Kenneth M Rice; Fernando Rivadeneira; Ron C Hoogeveen; João Daniel Fontes; Christa Meisinger; John F Keaney; Rozenn Lemaitre; Yurii S Aulchenko; Ramachandran S Vasan; Stephen Ellis; Stanley L Hazen; Cornelia M van Duijn; Jeanenne J Nelson; Winfried März; Heribert Schunkert; Ruth M McPherson; Heide A Stirnadel-Farrant; Bruce M Psaty; Christian Gieger; David Siscovick; Albert Hofman; Thomas Illig; Mary Cushman; Jennifer F Yamamoto; Jerome I Rotter; Martin G Larson; Alexandre F R Stewart; Eric Boerwinkle; Jacqueline C M Witteman; Russell P Tracy; Wolfgang Koenig; Emelia J Benjamin; Christie M Ballantyne Journal: Eur Heart J Date: 2011-10-14 Impact factor: 29.983
Authors: Parveen K Garg; Robyn L McClelland; Nancy S Jenny; Michael H Criqui; Philip Greenland; Robert S Rosenson; David S Siscovick; Neal Jorgensen; Mary Cushman Journal: Atherosclerosis Date: 2015-05-16 Impact factor: 5.162